![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
US FDA approval of the conformable Gore TAG thoracic endoprosthesis for multiple indications including aneurysm, traumatic transection and Type B dissection marks significant progress in minimally invasive therapies for the treatment of complex, life-threatening thoracic aortic pathology. This second generation device, with its enhanced flexibility and conformability, is providing improvements in both short- and long-term outcomes for many patients who may otherwise be denied life-saving treatment for thoracic aortic pathology.
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.
Key issues
The Conformable GORE TAG device (C-TAG) device provides endovascular repair of pathology involving the descending thoracic aorta.
The C-TAG device is a flexible, self-expanding endoprosthesis mounted and constrained on the leading end of a delivery catheter, and the system consist of two parts, the endoprosthesis itself and the delivery catheter.
The Gore C-TAG device is approved by the US FDA for the treatment of degenerative thoracic aortic aneurysms, thoracic aortic traumatic transection or other focal pathology (such as penetrating aortic ulcer) and for thoracic aortic Type B dissection.